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 28 
What is already known about this subject: 29 
• Therapeutic inhibition of the renin angiotensin system (RAS) has led to 30 
improvements in survival in patients with heart failure.  31 
• RAS inhibition has been associated with increased risk of acute kidney injury 32 
(AKI). 33 
• Patients at highest cardiovascular risk may be at higher risk of AKI due to 34 
additional comorbid factors. 35 
 36 
What this study adds: 37 
• We found risk factors for AKI in >60,000 patients prescribed RAS inhibitors 38 
were age, heart failure, diabetes, chronic kidney disease and comorbidity 39 
• Patients with greatest benefit from RAS inhibition are also at risk of AKI.  40 
• This association does not suggest causation; awareness of AKI is required in 41 
these patients.  42 
 43 
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Abstract 45 
Aims Therapy with angiotensin converting enzyme inhibitors (ACEi) and angiotensin 46 
receptor blockers (ARB) is a mainstay of treatment for heart failure (HF), diabetes 47 
mellitus (DM) and chronic kidney disease (CKD). These agents have been associated 48 
with development of acute kidney injury (AKI) during intercurrent illness. Risk factors 49 
for AKI in patients prescribed ACEi/ARB therapy are not well described. 50 
Methods We the incidence of AKI in patients commencing ACEi/ARB during 2009-51 
2015 using anonymised patient records. Hospital-coded AKI was defined from hospital 52 
episode statistics; biochemical AKI was ascertained from laboratory data. Risk factors 53 
for biochemically detected and hospitalised AKI were investigated.  54 
Results Of 61,318 patients prescribed ACEi/ARB, with 132,885 person years (py) 55 
follow up, there were 1,070 hospitalisations with AKI as a diagnoses recorded and a 56 
total of 4,645 AKI events, including AKI episodes indicated by biochemical KDIGO-57 
based creatinine change criteria.  Incidence of any AKI event was 35.0 per 1000- py, 58 
hospital-coded AKI was 7.8 per 1000-py and biochemical AKI was 33.7 per 1000-py. 59 
Independent risk factors in a multivariable model for hospital-coded AKI events were 60 
age, male gender, HF, diabetes, cerebrovascular disease, lower estimated glomerular 61 
filtration rate, socioeconomic deprivation, diuretic or non-steroidal anti-inflammatory 62 
use (all p<0.001).  63 
Conclusion In patients prescribed ACEi/ARB, the highest risk of AKI is associated 64 
with conditions which are considered strong evidence-based indications for their 65 
prescription. Socio-economic status is an under-reported risk factor for AKI with these 66 
agents. Strategies targeted at prevention of AKI may be of benefit, such as enhanced 67 
awareness based on higher risk comorbidities.  68 
 69 
70 
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Introduction 71 
Therapeutic inhibition of the renin angiotensin system with angiotensin converting 72 
enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) drugs is a mainstay 73 
of therapy for conditions associated with increased cardiovascular risk including 74 
hypertension, heart failure (HF), diabetes mellitus (DM) and proteinuric chronic kidney 75 
disease (CKD). This approach has been established following landmark clinical trials 76 
demonstrating efficacy of these agents in improving outcomes[1-8].  77 
There is evidence that patients taking renin angiotensin system inhibitors 78 
(RASi) with ACEi/ARB in combination with non-steroidal anti-inflammatory drugs 79 
(NSAIDs) and diuretics are at increased risk of AKI[9, 10]. In addition, it is commonly 80 
reported that RASi are associated with acute kidney injury (AKI), particularly in the 81 
setting of impaired renal perfusion[9, 10]. A commonly described scenario for this is 82 
when a patient becomes dehydrated e.g. due to a diarrhoeal illness[11] and 83 
background RASi treatment leads to failure of regulation of angiotensin II-dependent 84 
glomerular perfusion and renal hypoperfusion leading to AKI. However, the degree to 85 
which RASi are causal for AKI in this setting are debated[12] . AKI in association with 86 
RASi therapy is common and the incidence is rising, either due to more widespread 87 
prescribing of these agents in patients at risk of AKI, or alternatively due to better 88 
awareness of AKI, including coding AKI as a diagnosis during hospitalisation[13, 14].  89 
AKI is common and when severe may be life threatening, often requiring 90 
hospitalisation and potentially acute dialysis. The overall mortality for acute kidney 91 
injury is high, with 1-year survival less than 50% even in mild AKI[15]. In patients who 92 
recover, it is common (but not invariable) for renal function not to return to the baseline 93 
level, especially in the presence of pre-existing CKD[16, 17]. Nevertheless, longer 94 
term studies show very poor survival up to one year after discharge[16]. Strategies 95 
that can identify people with high risk of AKI or poor outcomes are needed. 96 
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AKI defined by the KDIGO criteria for diagnosis of AKI, based on small changes 97 
in creatinine, is associated with poor short and long term outcomes, irrespective of 98 
hospitalisation[18]. Electronic alerts (e-alerts) for biochemical AKI have been 99 
proposed as a mechanism for improving detection and management of AKI, although 100 
e-alerts need to be combined with education and clinical support to alter outcomes[19, 101 
20]. 102 
By linking demographic, clinical, prescribing and biochemical sources of patient 103 
data from both primary and secondary care, it is possible to ascertain the incidence 104 
of, and risk factors for AKI, including biochemical-only AKI detected by blood tests, 105 
and episodes of AKI requiring hospitalisation. The aim of this study, using novel 106 
linkage of electronic patient data in an area of social deprivation and high rates of 107 
cardiovascular disease[21], was to describe the incidence and risk factors for AKI 108 
among patients prescribed RASi therapy.  109 
  110 
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Methods 111 
Cohort 112 
Greater Glasgow and Clyde National Health Service (NHS) provides healthcare to a 113 
population of approximately 1.2million. The NHS Greater Glasgow and Clyde ‘Safe 114 
Haven’, is a secure environment whereby health data from different sources can be 115 
linked together and made available in de-identified form for analysis. It has been 116 
ethically approved by the ethics committee of NHS Greater Glasgow and Clyde. This 117 
specific project was approved Local Privacy Advisory Committee of the Safe Haven.  118 
All health episodes in Scotland are linked by the Community Health Index (CHI), a 119 
unique identifier for all patients. In this study, we used data related to NHS care, 120 
including patient records, prescribing, hospitalisations and laboratory testing. We 121 
defined patients included in the cohort as those incident users of RASi encashing at 122 
least one prescription for ACEi or ARB from the  prescription information system (PIS), 123 
which captures data of all ‘cashed’ prescriptions  in NHS Greater Glasgow and Clyde 124 
from Jan 2009-Dec 2015[22]. We excluded patients with prevalent use of RASi prior 125 
to 1/9/2009 and patients with a prior diagnosis of cancer (excluding non-melanoma 126 
skin cancer) at the time of commencement of RASi therapy. Patients entered the 127 
cohort at the date of their first prescription, and exited the cohort at death, at the last 128 
prescription date plus 30 days, to allow for a washout period, or at the end of the data 129 
extract from PIS. The makeup of the cohort is shown in Figure 1.  130 
Comorbidities at baseline were defined by the presence of a diagnosis of 131 
hypertension, heart failure (HF), diabetes mellitus (DM), cardiovascular disease 132 
(CVD), or cerebrovascular disease (CeVD), from general practitioner (GP) electronic 133 
records (termed ‘local enhanced service’ (LES)) data, as well as from ICD-10 codes 134 
from prior hospital admission records at cohort entry. A Charlson co-morbidity index 135 
was calculated for all patients[23]. PIS records for all patients were used to identify 136 
additional treatment with diuretics (loop, thiazide and potassium sparing) and non-137 
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steroidal anti-inflammatory drugs (NSAID). Patients were also classified as having 138 
chronic kidney disease (CKD) based on this being recorded by their GP within LES 139 
coding. We defined baseline kidney function as the mean estimated glomerular 140 
filtration rate (eGFR) calculated using the CKD-EPI formula in the year prior to cohort 141 
entry[24]. Serum creatinine measures were isotope dilution mass spectrometry 142 
aligned.   143 
The Scottish Government provide online calculators allowing use of patient 144 
postcode to generate divisions of socioeconomic deprivation, the Scottish Index of 145 
Multiple Deprivation (SIMD) (http://www.gov.scot/Topics/Statistics/SIMD). Using 146 
patient postcode, deprivation quintiles of deprivation status were calculated and 147 
categorised into most deprived (quintile 1) to least deprived (quintile 5). 148 
 149 
Definition of acute kidney injury (AKI) 150 
 Hospital-coded AKI was defined as a hospital admission with ICD-10 code N17 151 
in any diagnostic position on hospital discharge coding in the Scottish Morbidity 152 
Records 01 (SMR01). SMR01 collects data on all non-obstetric, non-psychiatric 153 
hospital discharges since 1968. Since 1989 SMR01 has been used to plan financial 154 
management of hospitals in order to ensure high completion rate. Internal audit of this 155 
data supports overall 89% accuracy for main condition diagnosis and similar or greater 156 
accuracy has been demonstrated in AKI in the United Kingdom[25, 26].  As a 157 
secondary event of interest, we captured the incidence, stage and severity of AKI 158 
episodes not associated with a hospitalisation episode, based on all creatinine 159 
measurements for individual patients from the laboratory database during the period 160 
of exposure. These were categorised as ‘community-based AKI’, where the creatinine 161 
measure used to define AKI was taken from a blood sample which during a period 162 
which did not coincide with any hospital admission and ‘all AKI’ which encompassed 163 
hospital-coded  AKI, community-based AKI and ‘other AKI events’ i.e. AKI episodes 164 
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occurring during a hospital admission but were not coded by hospital coding data on 165 
hospital discharge.  Biochemical AKI was defined using an algorithm aligned to the 166 
NHS e-alert AKI warning system currently implemented in NHS England for routine 167 
health care and as previously reported[27, 28]. AKI was diagnosed from the following 168 
criteria: 169 
1. Serum creatinine ≥1.5 times higher than the median of all creatinine values 8–170 
365 days ago 171 
2. Serum creatinine ≥1.5 times higher than the lowest creatinine within 7 days 172 
3. Serum creatinine >26 µmol/L higher than the lowest creatinine within 48 h 173 
 If one or more of these criteria were met, AKI was attributed to that date / 174 
measurement.  Our sources only resolved measurements to the level of date. When 175 
more than one value was recorded on a given day, the highest value was considered.  176 
Severity of AKI was based on the KDIGO definition applied to this algorithm[29].For 177 
every AKI identified above a staging was assigned per the following rules: 178 
• Stage 1: Serum creatinine ≥1.5 and < 2.0 times AKI baseline or >=26.0 µmol/l 179 
increase above AKI baseline 180 
• Stage 2: Serum creatinine >=2.0 and < 3.0 times AKI baseline 181 
• Stage 3: Serum creatinine 3.0 times AKI baseline or >=354 µmol/l increase 182 
above AKI baseline 183 
To avoid confounding by early changes in serum creatinine following instigation of 184 
ACEi/ARB therapy, we discounted serum creatinine measured <14 days following 185 
commencement of therapy. E-alerts were not used in the laboratory systems during 186 
the period of this study. We identified deaths and date of death by linkage to the 187 
National Records Scotland death certificates (NRS). 188 
 189 
 190 
 191 
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Statistical analyses 192 
The primary outcome was defined as the incidence of first AKI – either biochemical 193 
AKI detected in the community, or hospitalisation for AKI. Patients who died during 194 
follow-up without experiencing an AKI event were censored at death. Kaplan Meier 195 
survival curves were generated for time to first AKI in relation to: age, sex, SIMD, 196 
eGFR, diuretics use at baseline, NSAID use at baseline, use of diuretics or NSAID at 197 
baseline, prescription groups at baseline and history of co-morbidities, namely: 198 
hypertension, heart failure, diabetes, CKD, cerebrovascular disease and Charlson 199 
Index of co-morbidities. Univariable Cox proportional hazard models were fitted to 200 
obtain estimates of the association between each covariate and incident AKI, reported 201 
as hazard ratios with 95% confidence intervals. The proportional hazards assumption 202 
was assessed using Schoenfeld residuals, and the assumption was not met for several 203 
variables in each model. However, visual inspection of Kaplan-Meier plots suggested 204 
that these deviations were quite subtle, and the hazard ratios may be interpreted as 205 
giving the average association over the follow-up period. 206 
Multivariable Cox regression models were fitted to further analyse the associations 207 
between covariates and incident AKI.  A manual backwards selection procedure was 208 
used, with all covariates (except for the Charlson Index excluded on the basis it is 209 
comprised of multiple co-morbidities being tested in the Cox model) considered in the 210 
starting model. Covariates were sequentially excluded based on the p-value, to obtain 211 
a final model with all predictors making a significant contribution (at a 5% significance 212 
level) to the model. All other predictors were categorical. No adjustments were made 213 
for multiple comparisons. All analyses were carried out using the statistical software 214 
package R[30]. 215 
The data that support the findings of this study are not publicly available due to privacy 216 
or ethical restrictions. Further information on the handling of electronic health record 217 
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data used in this study are available here https://www.nhsggc.org.uk/about-218 
us/professional-support-sites/nhsggc-safe-haven/about-the-safe-haven/.  219 
 220 
Results  221 
 222 
Demographics of cohort and Incidence of AKI 223 
Figure 1 summarises how the cohort of incident RASi users was generated. During 224 
the study period 61,318 patients were prescribed ACEi/ARB. The mean age of the 225 
cohort was 59.8 years (SD 13.9), and 51.9% were male. 3,302 (5.4%) had HF, 8,807 226 
(14.4%) had diabetes, and the mean eGFR was 86.1ml/min/1.73m2 (SD 18.2). There 227 
were 7993 deaths during follow-up. 228 
During a median follow up of 1.92 yrs there were 1,070 hospital-coded AKI events, 229 
and 4,483 biochemical AKI episodes. In total, 4,645 patients had at least one AKI 230 
event during 132,885 person years (py) of follow up. Hospital-coded AKI and 231 
biochemical AKI overlapped, but were not mutually exclusive, as 162 patients had a 232 
hospital-coded AKI, without confirmatory biochemistry, where the patient had no 233 
available baseline kidney function tests. The incidence of all AKI events was 35.0 per 234 
1000-py, hospital-coded AKI was 7.8 per 1000-py and biochemical AKI was 33.7 per 235 
1000-py.  236 
 237 
Risk factors associated with AKI 238 
The patients at highest risk of AKI were those with most comorbidities. Data are 239 
presented on all AKI events in Table 1 (biochemical or hospital-coded AKI) as the 240 
overall pattern of risk factors associated with AKI were similar for both biochemical 241 
and hospital-coded AKI. Data on hospital-coded and biochemical AKI are presented 242 
separately in Tables 2 and 3. On univariable analyses of the association between 243 
baseline characteristics and incident AKI, the risk of AKI events increased with 244 
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increasing age, socioeconomic deprivation (Figure 2), lower eGFR, diuretic use, heart 245 
failure, diabetes, a diagnosis of CKD, cerebrovascular disease, or increasing Charlson 246 
co-morbidity index. On univariable analysis there was no association with NSAID use 247 
in isolation (Table 2 and 3), and combined NSAID and diuretic use did not confer 248 
higher risk than diuretic use alone.  249 
Risk of AKI was highest in three distinct (though overlapping) groups. Patients with 250 
heart failure had an incidence of hospital-coded AKI of 29.4 per 1000-py and 251 
biochemical AKI of 122.4 per 1000-py. Similar figures were observed for patients with 252 
CKD with hospital-coded AKI incidence of 40.9 and biochemical AKI incidence of 253 
117.6 per 1000-py. Using Charlson index of 3 or more as a measure of greatest 254 
comorbidity identified a group of extremely high risk of both hospital-codeAKI and 255 
biochemical AKI (40.1 and 166.8 per 1000-py respectively, Tables 2 and 3).  256 
Using a multivariable Cox proportional hazards model, independent predictors of AKI 257 
were male gender, increasing age, increasing socioeconomic deprivation, diuretic use, 258 
NSAID use, history of heart failure, diabetes mellitus, eGFR, and history of 259 
cerebrovascular disease, as presented in Table 4. It is notable that male gender was 260 
associated with higher risk of AKI based on multivariable analysis, despite female 261 
gender being higher risk on univariable analysis.  262 
 263 
 264 
  265 
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Discussion 266 
This is one of the first reports using routine clinical data to quantify risk factors for AKI 267 
in ACEi/ARB users. Patients with increasing comorbidity were at highest risk of AKI, 268 
with many conditions associated with increased risk of AKI, including HF, DM, and 269 
CKD – conditions where there is high grade evidence for using these drugs in 270 
accordance with national guidelines[31-33]. Patients concomitantly prescribed 271 
diuretics and NSAIDSs are at greater risk of AKI, as observed by others[9, 10]. 272 
Amongst incident patients prescribed ACEi/ARB medication, we found a similar rate 273 
of AKI episodes associated with a hospital admission to a previous cohort of 274 
ACEi/ARB users[14]. The incidence of biochemical AKI based on internationally 275 
recognised creatinine change criteria was approximately two-fold higher than has 276 
previously been reported for the general population in the Grampian region[34].  277 
 278 
Risk factors for both biochemical and hospital-coded AKI 279 
 The recognition of association of AKI with prescription of ACEi/ARB therapy in 280 
the setting of relative hypovolaemia is well established[11, 35]. However, using 281 
observational prescribing data combined with biochemical flagging and hospitalisation 282 
coding records for AKI, we identify patients at highest risk of AKI whilst prescribed 283 
these agents. Caution is required in interpreting any association between ACEi/ARB 284 
therapy and AKI as causal.  Recent studies using national primary care data did not 285 
demonstrate higher risk of hospitalisation with AKI overall, or following common 286 
infections including gastroenteritis, among users of ACEi/ARB compared to other 287 
antihypertensives[36]. Our data demonstrate that patients with the most compelling 288 
evidence-based indications for prescription of ACEi/ARB therapy are those at highest 289 
risk of subsequent AKI. These indications include HF, CKD and/or DM with proteinuria 290 
where there are data from high quality randomised controlled trials (RCTs) suggesting 291 
benefit with these agents[1, 4-6, 8, 37, 38]. The evidence for benefits of ACEi are most 292 
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compelling in patients with HF and reduced left ventricular ejection fraction[8, 38]. 293 
These agents are strongly recommended in the recent European Society of 294 
Cardiology (ESC) and American Heart Association (AHA) guidelines for management 295 
of HF[31, 32]. However, despite our observation that AKI is common among those with 296 
HF on ACEi/ARB, AKI is described as ‘rare’ in HF patients in the ESC guidelines[31] 297 
and monitoring of renal function is seen as ‘good practice’ with no mention of AKI in 298 
the AHA guidelines[32]. Biochemically detected AKI events may represent natural 299 
fluctuations in serum creatinine occurring in patients with HF talking RASi often in 300 
combination with diuretic therapy. These changes may not represent ‘AKI’ with any 301 
intrinsic renal damage and may simply reflect changes in serum creatinine in the 302 
setting of haemodynamic perturbation as glomerular perfusion pressure responds to 303 
changes in hydration status. Nevertheless, greater rises in serum creatinine in patients 304 
requiring ACEi/ARB therapy highlights a group of patients at greater mortality risk 305 
during follow up[39]. Therefore, we would simply state that increased awareness of 306 
AKI in patients with HF is required and sensitivity is needed in interpreting AKI alerts 307 
in these patients. 308 
 There is evidence that these agents delay progression of proteinuric CKD 309 
and/or improve outcomes in patients with diabetes and albuminuria [5, 40]. These 310 
results suggest that the groups potentially deriving most benefit from these agents are 311 
at highest risk of being hospitalised with AKI, albeit in observational data with no 312 
control group. The clinical significance of these biochemically detected AKI events is 313 
unclear, and further studies are required to determine if these events confer any 314 
longer-term risk of decline in renal function. Whilst hospitalised AKI increases risk of 315 
subsequent CKD[41, 42], it is less clear whether subtler acute, transient declines in 316 
renal function lead to longer term renal risk.  317 
 318 
 319 
 14 
Multi-morbidity and AKI risk  320 
 In an ageing population with increasing comorbidity, the association of 321 
Charlson index and AKI episodes is concerning. These patients in this cohort were 322 
prescribed ACEi/ARBs based on evidence from randomised controlled trials, which 323 
were performed over 15 years ago. It should be recognised that in an aging society 324 
where multi-morbidity is more common, these RCTs may no longer be representative 325 
of many contemporary patients prescribed these agents. This was highlighted in a 326 
report from a similar population as our study, whereby 23.2% were classified as ‘multi-327 
morbid’[43]. On the other hand, undertreatment of multimorbid patients with HF is likely 328 
to be associated with poor survival. Multi-morbidity is common in patients from a 329 
socially deprived background[43]. We observed that social deprivation status was 330 
associated with increased AKI risk. Therefore, AKI risk in patients prescribed 331 
ACEi/ARB therapy is associated with a cluster of interrelated risk factors including 332 
number of comorbid conditions, concomitant therapy and socioeconomic deprivation.   333 
The optimal strategy to address the risk of AKI in the community in patients 334 
taking ACEi/ARB is unknown. General practitioners should be aware that that the most 335 
comorbid patients are most at risk and need close monitoring, particularly during acute 336 
illness. Initiatives to tackle this problem are currently being investigated such as ‘sick 337 
day rules’ where patients taking these drugs are advised to stop them during acute 338 
illness. This strategy requires resources for patient education and to date is not 339 
supported by clinical evidence of efficacy[44, 45].  340 
   341 
Strengths and limitations of this study 342 
 The strength of these analyses include a large sample size, with excellent 343 
coverage of the population studied, avoiding sampling biases. The results 344 
demonstrating similar risk factors for hospital coded and biochemical AKI suggest that 345 
our analysis methods for assessing influence of comorbid variables were robust and 346 
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give a consistent message.  We do not have a control group so the incidence of AKI 347 
in patients with these comorbid conditions not prescribed ACEi/ARB is unknown.  348 
Defining the most appropriate patients to study as a control group is challenging. There 349 
would be biases in selecting a group of patients commenced on an alternative class 350 
of antihypertensive medication such as calcium channel blockers. This has been 351 
explored in other studies with only small increases of AKI incidence with ACEi/ARB in 352 
comparison to patients exposed to antihypertensive regimes not including 353 
ACEi/ARB14. In the case of HF, it would be unusual not to be treated with ACEi/ARB 354 
therapy.   355 
 We acknowledge further limitations with these analyses. AKI without clinical 356 
symptoms may be diagnosed more frequently in patients having frequent blood 357 
samples (ascertainment bias). We are unaware of the indication for taking the blood 358 
sample leading to a record in the laboratory database.  The incidence of biochemical 359 
AKI in untested patients is unknowable. Whilst we use the term ‘hospital-coded AKI’, 360 
it is possible and indeed likely, that AKI was one of a number of diagnoses coded 361 
during a hospitalisation episode, rather than the sole diagnosis. There may be coding 362 
bias in either direction with hospital-coded AKI, where AKI is added as a diagnosis in 363 
the absence of biochemical evidence, or where AKI was present but not recorded as 364 
a diagnosis on hospital discharge. The incidence of biochemically diagnosed AKI was 365 
particularly high in patients with CKD. Whilst these patients are likely to be at high risk 366 
of AKI, the use of an algorithm based on serum creatinine, may lead to a higher 367 
incidence of AKI related to how the algorithm diagnoses patients with an AKI event.  It 368 
is possible that some of the co-morbid conditions have not been coded in the health 369 
care records, leading to an under-reporting of the Charlson co-morbidity index.  This 370 
This can be seen with chronic kidney disease, where only 1989 subjects have been 371 
coded as having CKD by their general practitioner despite 4553 patients having a 372 
recorded GFR <59ml/min/m2 (which is likely to be consistent with CKD). 373 
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 The prescribing records indicate that a patient collected a prescription, rather 374 
than took the prescribed medication. Although we describe CKD as an ‘indication’ for 375 
therapy, we do not have proteinuria data and therefore it is unclear how strong this 376 
indication was for ACEi/ARB therapy and or whether proteinuria alters risk of AKI.  377 
   378 
Conclusion 379 
  We describe associations of various clinical variables with increased risk of 380 
AKI in patients prescribed ACEi/ARB therapy. However, we do not describe these 381 
relationships as causal. The overwhelming evidence demonstrates that these 382 
medicines have heralded remarkable improvements in survival in patients with HF, in 383 
particular[8, 38] 384 
 We demonstrate that older patients with heart failure, diabetes, CKD, lower 385 
socioeconomic status and prior stroke are at highest risk of AKI, both hospital-coded 386 
and biochemically detected in the community. Biochemical AKI may serve as a risk 387 
marker for future adverse events. Further work is required to identify strategies to 388 
minimise risk of hospital-coded and/or biochemical AKI in patients receiving therapy 389 
with these agents.  390 
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N 
Eligib
le 
N 
event
s 
Person 
years 
follow-up 
Event rate 
(per 1000-
py) 
HR (95% CI);p-value 
All  61318 4645 132885.0 35.0 - 
 Female 
Male 
29468 
31850 
2302 
2343 
62080.5 
70804.5 
37.1 
33.1 
- 
0.90(0.85,0.95);p<0.001 
Age 
≤50 
51-60 
61-70 
≥ 71 
15603 
16554 
13984 
15177 
517 
752 
1027 
2349 
35424.9 
37818.5 
31116.5 
28525.1 
14.6 
19.9 
33.0 
82.3 
- 
1.36(1.22,1.52);p<0.001 
2.25(2.03,2.50);p<0.001 
5.50(5.00,6.05);p<0.001 
SIMD Quintile 
1(Most deprived)* 
2 
3 
4 
5(Least deprived) 
Missing 
21087 
10203 
7848 
6829 
10065 
5286 
1895 
872 
618 
458 
581 
221 
45699.5 
22126.9 
17327.9 
15261.7 
22614.7 
9854.3 
41.5 
39.4 
35.7 
30.0 
25.7 
22.4 
1.61(1.46,1.76);p<0.001 
1.53(1.38,1.70);p<0.001 
1.39(1.24,1.55);p<0.001 
1.17(1.03,1.32);p=0.014 
-  
0.84(0.72,0.98);p=0.026 
baseline 
eGFR (ml/min)* 
  
≤ 29 
30-59 
> 59 
Missing 
281 
4271 
45408 
11358 
91 
973 
3147 
434 
361.4 
7673.9 
101000.3 
23849.3 
251.8 
126.8 
31.2 
18.2 
7.61(6.18,9.37);p<0.001 
3.97(3.70,4.27);p<0.001 
- 
0.58(0.52,0.64);p<0.001 
Diuretics No Yes 
45862 
15456 
2683 
1962 
100391.6 
32493.3 
26.7 
60.4 
- 
2.25(2.12,2.38);p<0.001 
NSAID No Yes 
37672 
23646 
3067 
1578 
87595.3 
45289.7 
35.0 
34.8 
- 
0.96(0.90,1.02);p=0.188 
Prescription 
groups 
None 
NSAID only 
Diuretics only 
Diuretic + NSAID 
28534 
17328 
9138 
6318 
1772 
911 
1295 
667 
67136.8 
33254.8 
20458.5 
12034.8 
26.4 
27.4 
63.3 
55.4 
- 
1.00(0.92,1.08);p=0.991 
2.39(2.22,2.56);p<0.001 
2.02(1.85,2.21);p<0.001 
Hypertension No Yes 
46939 
14379 
2978 
1667 
100661.3 
32223.7 
29.6 
51.7 
- 
1.76(1.66,1.87);p<0.001 
Heart failure No Yes 
58016 
3302 
3840 
805 
126568.0 
6316.9 
30.3 
127.4 
- 
4.12(3.81,4.44);p<0.001 
Diabetes No Yes 
52511 
8807 
3702 
943 
113698.8 
19186.2 
32.6 
49.1 
- 
1.51(1.40,1.62);p<0.001 
CKD No Yes 
59330 
1988 
4169 
476 
129127.3 
3757.6 
32.3 
126.7 
- 
3.86(3.51,4.25);p<0.001 
Cerebrovascul
ar disease 
No 
Yes 
58567 
2751 
4226 
419 
127671.1 
5213.9 
33.1 
80.4 
- 
2.37(2.15,2.62);p<0.001 
Charlson index 
0 
1 
2 
3+ 
44429 
10477 
4013 
2399 
2200 
1117 
668 
660 
99182.5 
21975.7 
7910.3 
3816.5 
22.2 
50.8 
84.4 
172.9 
- 
2.27(2.11,2.44);p<0.001 
3.74(3.43,4.08);p<0.001 
7.43(6.81,8.11);p<0.001 
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 573 
  N 
Eligible 
N 
events 
Person 
years 
follow-
up 
Event 
rate 
(per 
1000-
py) 
HR (95% CI);p-value 
All  61318 1070 137874.6 7.8 - 
 Female 
Male 
29468 
31850 
515 
555 
64508.1 
73366.4 
8.0 
7.6 
- 
0.95(0.84,1.07);p=0.373 
Age 
≤50 
51-60 
61-70 
≥ 71 
15603 
16554 
13984 
15177 
94 
147 
211 
618 
36166.1 
38790.8 
32339.4 
30578.2 
2.6 
3.8 
6.5 
20.2 
- 
1.46(1.12,1.89);p=0.004 
2.51(1.97,3.21);p<0.001 
7.86(6.32,9.76);p<0.001 
SIMD Quintile 
1(Most deprived) 
2 
3 
4 
5(Least deprived) 
Missing 
21087 
10203 
7848 
6829 
10065 
5286 
431 
214 
141 
106 
128 
50 
47760.9 
23030.1 
18018.9 
15740.6 
23242.0 
10082.1 
9.0 
9.3 
7.8 
6.7 
5.5 
5.0 
- 
1.03(0.87,1.21);p=0.729 
0.87(0.72,1.05);p=0.141 
0.75(0.60,0.92);p=0.007 
0.61(0.50,0.74);p<0.001 
0.56(0.42,0.75);p<0.001 
baseline 
eGFR (ml/min) 
  
≤ 29 
30-59 
> 59 
Missing 
281 
4271 
45408 
11358 
35 
311 
620 
104 
429.7 
8509.1 
104633.5 
24302.2 
81.5 
36.5 
5.9 
4.3 
- 
0.45(0.31,0.63);p<0.001 
0.07(0.05,0.10);p<0.001 
0.05(0.04,0.08);p<0.001 
Diuretics No Yes 
45862 
15456 
558 
512 
103495.5 
34379.0 
5.4 
14.9 
- 
2.76(2.45,3.11);p<0.001 
NSAID No Yes 
37672 
23646 
729 
341 
90829.8 
47044.8 
8.0 
7.2 
- 
0.91(0.80,1.04);p=0.170 
Prescription 
groups 
None 
NSAID only 
Diuretics only 
Diuretic + NSAID 
28534 
17328 
9138 
6318 
375 
183 
354 
158 
69202.2 
34293.3 
21627.5 
12751.5 
5.4 
5.3 
16.4 
12.4 
- 
1.00(0.83,1.19);p=0.971 
3.02(2.61,3.49);p<0.001 
2.31(1.92,2.79);p<0.001 
Hypertension No Yes 
46939 
14379 
637 
433 
103767.6 
34107.0 
6.1 
12.7 
- 
2.06(1.83,2.33);p<0.001 
Heart failure No Yes 
58016 
3302 
861 
209 
130763.7 
7110.8 
6.6 
29.4 
- 
4.50(3.87,5.23);p<0.001 
Diabetes No Yes 
52511 
8807 
828 
242 
117630.7 
20243.9 
7.0 
12.0 
- 
1.70(1.47,1.96);p<0.001 
CKD No Yes 
59330 
1988 
897 
173 
133647.4 
4227.2 
6.7 
40.9 
- 
6.09(5.18,7.17);p<0.001 
Cerebrovascular 
disease 
No 
Yes 
58567 
2751 
961 
109 
132322.9 
5551.7 
7.3 
19.6 
- 
2.72(2.23,3.31);p<0.001 
Charlson index 
0 
1 
2 
3+ 
44429 
10477 
4013 
2399 
446 
262 
185 
177 
101681.2 
23213.8 
8567.4 
4412.1 
4.4 
11.3 
21.6 
40.1 
- 
2.58(2.22,3.01);p<0.001 
4.97(4.18,5.90);p<0.001 
9.29(7.81,11.06);p<0.001 
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  N 
Eligible 
N 
events 
Person 
years 
follow-up 
Event 
rate 
(per 
1000-
py) 
HR (95% CI);p-value 
All  61318 4483 133045.2 33.7 - 
 Female 
Male 
29468 
31850 
2231 
2252 
62153.8 
70891.4 
35.9 
31.8 
- 
0.89(0.84,0.94);p<0.001 
Age 
≤50 
51-60 
61-70 
≥ 71 
15603 
16554 
13984 
15177 
507 
738 
995 
2243 
35432.1 
37834.1 
31170.9 
28608.1 
14.3 
19.5 
31.9 
78.4 
- 
1.36(1.22,1.53);p<0.001 
2.22(2.00,2.47);p<0.001 
5.33(4.84,5.87);p<0.001 
SIMD Quintile 
1(Most deprived) 
2 
3 
4 
5(Least deprived) 
Missing 
21087 
10203 
7848 
6829 
10065 
5286 
1837 
841 
597 
442 
556 
210 
45770.1 
22143.5 
17345.2 
15273.6 
22645.9 
9866.8 
40.1 
38.0 
34.4 
28.9 
24.6 
21.3 
- 
0.95(0.87,1.03);p=0.183 
0.86(0.78,0.94);p=0.001 
0.72(0.65,0.80);p<0.001 
0.61(0.56,0.68);p<0.001 
0.51(0.44,0.59);p<0.001 
baseline 
eGFR (ml/min) 
  
≤ 29 
30-59 
> 59 
Missing 
281 
4271 
45408 
11358 
87 
914 
3070 
412 
364.9 
7742.4 
101061.2 
23876.7 
238.4 
118.1 
30.4 
17.3 
- 
0.51(0.41,0.64);p<0.001 
0.14(0.11,0.17);p<0.001 
0.08(0.06,0.10);p<0.001 
Diuretics No Yes 
45862 
15456 
2589 
1894 
100478.2 
32567.0 
25.8 
58.2 
- 
2.25(2.12,2.38);p<0.001 
NSAID No Yes 
37672 
23646 
2960 
1523 
87714.4 
45330.8 
33.7 
33.6 
- 
0.96(0.90,1.02);p=0.181 
Prescription groups 
None 
NSAID only 
Diuretics only 
Diuretic + NSAID 
28534 
17328 
9138 
6318 
1716 
873 
1244 
650 
67199.4 
33278.8 
20515.0 
12052.0 
25.5 
26.2 
60.6 
53.9 
- 
0.99(0.91,1.07);p=0.778 
2.36(2.20,2.54);p<0.001 
2.03(1.86,2.22);p<0.001 
Hypertension No Yes 
46939 
14379 
2890 
1593 
100733.8 
32311.4 
28.7 
49.3 
- 
1.73(1.63,1.84);p<0.001 
Heart failure No Yes 
58016 
3302 
3707 
776 
126706.9 
6338.3 
29.3 
122.4 
- 
4.10(3.79,4.43);p<0.001 
Diabetes No Yes 
52511 
8807 
3577 
906 
113820.9 
19224.3 
31.4 
47.1 
- 
1.50(1.39,1.61);p<0.001 
CKD No Yes 
59330 
1988 
4037 
446 
129251.1 
3794.1 
31.2 
117.6 
- 
3.71(3.36,4.09);p<0.001 
Cerebrovascular 
disease 
No 
Yes 
58567 
2751 
4083 
400 
127816.4 
5228.8 
31.9 
76.5 
- 
2.34(2.11,2.59);p<0.001 
Charlson index 
0 
1 
2 
3+ 
44429 
10477 
4013 
2399 
2132 
1078 
633 
640 
99248.4 
22025.8 
7933.0 
3838.0 
21.5 
48.9 
79.8 
166.8 
- 
2.26(2.10,2.43);p<0.001 
3.64(3.34,3.98);p<0.001 
7.38(6.76,8.07);p<0.001 
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 588 
Table 4  Multivariable model for association between predictors and risk of any 589 
AKI event. Reference group for SIMD: SIMD 1(most deprived) 590 
 591 
  592 
 Hazard Ratio 95% C.I p-value 
Gender (Male) 
Age at entry (per 10 year increase) 
SIMD 2 
SIMD 3 
SIMD 4 
SIMD 5(Least deprived) 
Diuretics (Yes) 
NSAID (Yes) 
History of heart failure (Yes) 
eGFR at baseline (per 10 units increase) 
History of diabetes (Yes) 
History of CEVD (Yes) 
1.20 
1.31 
0.88 
0.82 
0.69 
0.56 
1.32 
1.16 
2.57 
0.80 
1.35 
1.46 
(1.13,1.29) 
(1.27,1.35) 
(0.81,0.96) 
(0.75,0.91) 
(0.62,0.77) 
(0.51,0.62) 
(1.21,1.44) 
(1.06,1.27) 
(2.37,2.79) 
(0.78,0.82) 
(1.25,1.46) 
(1.32,1.63) 
p<0.001 
p<0.001 
p=0.003 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p=0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
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Legends to Figures 593 
Figure 1 Flow diagram showing how cohort was generated for analysis from 594 
electronic patient records 595 
Figure 2 Kaplan Meier curves for incidence of any AKI after first prescription of 596 
ACEi/ARB by SIMD Quintile 597 
 598 
 599 
 600 
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